The Rise Journal
Evidence, not hype.
Clear reads on the molecules, protocols, and clinical data behind modern longevity medicine.
Health · September 3, 2026
Testosterone therapy: what's hype and what's evidence
TRT is everywhere. Here is what the data says about who actually benefits, what the real risks are, and why a good protocol is rarely testosterone alone.
Read article
Health · August 20, 2026
GHK-Cu: the copper peptide with 50 years of research behind it
Copper peptides are having a moment in skincare, but GHK-Cu has been studied since 1973. Here is what the clinical evidence actually shows.
Read article
Health · August 13, 2026
Beyond weight loss: the potential benefits of GLP-1s
GLP-1s have moved far beyond weight loss. Here is what the latest research shows about their effects on heart, kidneys, liver, sleep, brain, and cravings.
Read article
Health · August 6, 2026
Testosterone for women: why it matters
Women have more testosterone than estrogen, but testosterone in women is barely tested or treated. Here is why that is about to change.
Read article
Health · July 30, 2026
How GLP-1 sourcing works in 2026 — and how to stay safe
GLP-1 sourcing looks very different than it did two years ago. Here is the new legal landscape and why licensed pharmacies matter more than ever.
Read article
Announcements · July 25, 2026
The FDA just voted on 7 peptides. Here's what changed (and what didn't)
The FDA's advisory panel just voted on BPC-157 and six other peptides. Here is what happened and what it means for patients.
Read article
Health · July 22, 2026
What are peptides and why is everyone taking them?
Peptides are everywhere in wellness — from GLP-1s to BPC-157. Here is what they are, why they are trending, and what the clinical evidence actually shows.
Read article